Riskpilot← Back to searchSign inGet full accessPhargentis AB
ABActiveOrg 5593400467Älvsåkersgränd 46Manufacture of pharmaceutical preparations · NACE 2120Est. 20210 employees
Revenue 2024
SEK 229K
EBITDA margin
-300.9%
+73% vs 2023
Equity ratio
92.6%
Financial strength
Net profit 2024
SEK -69,4M
-5896% vs 2023
| Revenue | SEK 229K | — |
| EBITDA | SEK -689K | +73% |
| Net profit | SEK -69,4M | -5896% |
| Total assets | SEK 13M | -84% |
| Equity | SEK 12M | -85% |
| Employees | 0 | — |
Legal name
Phargentis AB
Org number
5593400467
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
12 oktober 2021
Share capital
SEK 1 400 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna eller en av dem i förening med Tam, Andrea Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolagets verksamhetsföremål är att direkt eller indirekt bedriva utveckling, registrering, marknadsföring, licensiering och kommersialisering av läkemedel som behandlar luftvägssjukdomar.
Address
Älvsåkersgränd 46
Email
fredrik@axelero.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 229 |
| Staff expenses | — | — | — | — |
| EBITDA | −1 123 | −3 821 | −2 565 | −689 |
| Depreciation & amort. | −0 | −0 | −0 | −0 |
| EBIT | −1 123 | −3 821 | −2 565 | −689 |
| Net financials | — | 530 | 1 407 | −68 749 |
| Profit before tax | −1 123 | −3 291 | −1 158 | −69 438 |
| Tax | −0 | −0 | −0 | −0 |
| Net profit | −1 123 | −3 291 | −1 158 | −69 438 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 3 277 | 83 623 | 82 854 | 12 997 |
| Equity | 1 902 | 82 627 | 81 469 | 12 031 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 1 375 | 996 | 1 385 | 966 |
| Total debt | 1 375 | 996 | 1 385 | 966 |
EBITDA margin
-300.9%
This company
15.8%
Market median
-2004% vs market
20212024
Equity ratio
92.6%
This company
38.2%
Market median
+142% vs market
20212024
Return on equity
-577.2%
This company
18.4%
Market median
-3237% vs market
20212024
Net profit margin
-30322.3%
This company
8.1%
Market median
-374449% vs market
20212024
Asset turnover
0.02×
This company
1.12×
Market median
-98% vs market
20212024
Debt / equity
0.08×
This company
0.62×
Market median
+87% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-10-01 – 2021-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HF Chief Auditor | Chief Auditor | 2022 | — | — |
AT Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
FP Chief Auditor | Chief Auditor | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Chairman | 2025 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Deputy Board Member | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
CHEMHOLDING SA | Company | 51.0% | 51.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
CHEMHOLDING SA
Phargentis AB (this company)PHARGENTIS SAPhargentis SaPhargentis ASBoard members of Phargentis AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Halvar Folke Mattias Lötborn | Chief Auditor | 0 companies |
| Andrea Tam | Chief Executive Officer | 0 companies |
| Filip Patrik Laurin | Chief Auditor | 0 companies |
| Anton van Troostenburg de Bruyn | Board of Directors | 0 companies |
| Hans Jarl Rutger Arnhult | Deputy Board Member | 0 companies |
| Bo Daniel Falk | Deputy Board Member | 0 companies |
| Viktor Elias Bergman Gullmark | Deputy Board Member | 0 companies |
| Emma Maria Birgitta Wik | Deputy Board Member | 0 companies |
| Anna Matilda Sjödin | Deputy Board Member | 0 companies |
| Rudolf Seigfried Dudler | Board of Directors | 0 companies |
| Lars Anders Larsson | Board of Directors | 0 companies |
| Bernd Stoiber | Board of Directors | 0 companies |
| Emelie Sofia Bergh | Deputy Board Member | 0 companies |
| Ashish Gupta | Board of Directors | 0 companies |
| Karl Fredrik Sjövall | Board of Directors | 0 companies |
| Anna Carolina Maria Bjarnhagen | Deputy Board Member | 0 companies |
| Rudolf Siegfried Dudler | Chairman | 0 companies |
| Rolf Stefan Janse | Deputy Board Member | 0 companies |
| LEIF BJERMER | Board of Directors | 0 companies |
| Mari Sinikka Kovaniemi Feldt | Deputy Board Member | 0 companies |
| Olina Kristina Maria Wåhlstedt | Deputy Board Member | 0 companies |